国产可降解涂层雷帕霉素药物洗脱支架在冠心病介入治疗中的疗效及安全性(2)
http://www.100md.com
2011年2月5日
 |
| 第1页 |
参见附件(2690KB，2页)。
[4] 韩雅玲，荆全民，陈学智，等.国产生物降解涂层雷帕霉素洗脱支架置入术治疗冠心病一年结果：国内单项单中心注册研究.中国循环杂志,2008,23(1)5-8.
[5] Smith SC,Dove JT,Kennedy JM,et al.ACC/AHA guidelines of percutaneous coronary interventions(revision of the 1993 PTCA guidelines-executive summary).A report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines(committee to revise the 1993 guidelines for percutaneous transluminalcoronaryangioplasty).J Am Coll Cardiol,2001,37:2215-2239.
[6] Holmes DR，Leon MB,Moses JW,et al.Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial,Arandomized Trial of aSirolimus-Eluting Stent Versus a Standard Stent in Patients at HighRisk forCoronayRestenosis.Circulation,2004,109:634-640.
[7] Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenoses in a native coronary artery.Neng J Med,2003,349:1315-1323.
[8] Steven O,Andrew R.The development of rapamycin and its applicationto stent restenosis.Circulation,2001,104:852-855.
您现在查看是摘要介绍页，详见PDF附件(2690KB，2页)。